Table 3.
ERP results of control/drug-naive/antipsychotic-short-exposure groups (SD in parentheses).a
| Control (n = 120) | Drug-naive (n = 21) | Antipsychotic short exposure (n = 21) | Statistics | ||
|---|---|---|---|---|---|
|
Post hoc Scheffe p values |
Effect size (Cohen’s d) | ||||
| A | B | C | |||
| MMN Fz | −1.36 (0.81) | −1.08 (0.88) | −1.00 (0.67) | A vs. B: 0.396 A vs. C: 0.267 B vs. C: 0.967 |
0.34 0.45 0.10 |
| P50 | |||||
| S1 amplitude | 2.44 (1.06) | 2.77 (1.77) | 2.33 (1.00) | A vs. B: 0.572 A vs. C: 0.936 B vs. C: 0.551 |
0.29 0.10 0.31 |
| S2 amplitudeb | 1.09 (0.64) | 1.32 (0.56) | 1.56 (1.02) | A vs. B: 0.480 A vs. C: 0.027b B vs. C: 0.600 |
0.36 0.67 0.28 |
| P50 ratio | 0.51 (0.34) | 0.54 (0.24) | 0.71 (0.45) | A vs. B: 0.942 A vs. C: 0.083 B vs. C: 0.402 |
0.09 0.56 0.46 |
| P50 difference | 1.35 (1.07) | 1.45 (1.51) | 0.77 (1.23) | A vs. B: 0.947 A vs. C: 0.141 B vs. C: 0.239 |
0.09 0.53 0.50 |
| N100 | |||||
| S1 amplitude | 6.73 (3.27) | 6.06 (3.01) | 5.61 (2.96) | A vs. B: 0.751 A vs. C: 0.391 B vs. C: 0.923 |
0.21 0.35 0.15 |
| S2 amplitude | 2 (1.31) | 2.64 (0.92) | 2.32 (1.56) | A vs. B: 0.209 A vs. C: 0.631 B vs. C: 0.783 |
0.50 0.24 0.24 |
| N100 ratio | 0.36 (0.31) | 0.50 (0.21) | 0.52 (0.42) | A vs. B: 0.270 A vs. C: 0.149 B vs. C: 0.989 |
0.47 0.49 0.06 |
| N100 difference | 4.73 (3.35) | 3.43 (2.40) | 3.30 (2.86) | A vs. B: 0.336 A vs. C: 0.214 B vs. C: 0.993 |
0.40 0.43 0.05 |
a
Some subjects failed to stay before the ERP session was terminated. The number of analyzable P50/N100 subjects was 15 for drug-naive and 18 for antipsychotic short exposure. The number of analyzable MMN subjects was 18 for drug-naive and 16 for antipsychotic short exposure.
b
Post hoc Scheffe test revealed significant differences between control and antipsychotic-short-exposure groups (p = 0.027).